Rochester: 12:15 pm, Gonda 8-104/Joseph 1-242
Florida: 1:15 pm, MA 3-051S

Headache
Dev Mehta, D.O.
"A Brief Look at What's New on the Horizon for Migraine, Cluster Headache, and Neuromodulatory Devices"

Learning objective:
Identify new medications - Lasmitidan (Reyvow), Ubrogepant (Ubrevly), Eptinezumab, Galcanezumab (Emgality) -  for both migraine and cluster headache and the Nerivio Migra (neuromodulatory device)

The presenter (nor spouse/partner) does not have a relevant financial relationship to disclose and does not intend to discuss an off-label/investigative use of a commercial product/device.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here.

ATTENDANCE/CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance.  All learners are encouraged to text attendance regardless of credit needs.  This number is only used for receiving text messages related to tracking attendance.  Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows. 

TRANSCRIPT
Any credit or attendance awarded from this series will appear on your Transcript.